Literature DB >> 1990951

Protective effect of theophylline on bronchial hyperresponsiveness in patients with allergic rhinitis.

M Aubier1, J Levy, C Clerici, F Neukirch, F Cabrières, D Herman.   

Abstract

Disorders of the upper respiratory tract, particularly allergic rhinitis are commonly associated with bronchial hyperresponsiveness. The latter may be responsible for chronic cough, a common symptom in patients with allergic rhinitis, which, as previously shown, can be the sole presenting manifestation of bronchial hyperresponsiveness. Theophylline is widely used in patients with asthma for its bronchodilator effect, whereas its action on bronchial reactivity is controversial. The aim of this study was to determine the effect of theophylline administration on bronchial hyperresponsiveness in patients with allergic rhinitis complaining of chronic cough. Fourteen patients were studied. All of them were judged atopic on the basis of positive skin tests to common allergens. During control, spirometry, flow-volume curves and specific airway conductance (SGaw) were measured. Bronchial challenges were then performed with increasing concentrations of carbachol, and dose-response curves were constructed. The concentration of carbachol, which decreased SGaw by 35% from baseline (PD35) was determined by interpolating from the dose-response curve. After control measurements patients received in a randomized, double-blind crossover fashion either theophylline 10 mg/kg/day orally or placebo for 30 days. Measurements were then redone. After a washout period of 8 days the measurements were repeated, and patients received theophylline or placebo for a second period of 30 days. Measurements were again performed at the end of this last study period. During control all patients had normal baseline lung function data and showed marked bronchial hyperresponsiveness, PD35 amounting to 26 +/- 7 micrograms of carbachol (normal value greater than 160 micrograms). No significant changes in PD35 were noted after placebo and washout when compared with control values.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1990951     DOI: 10.1164/ajrccm/143.2.346

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  6 in total

Review 1.  Allergic rhinitis/asthma interrelationships.

Authors:  T B Casale; B V Amin
Journal:  Clin Rev Allergy Immunol       Date:  2001-08       Impact factor: 8.667

2.  The airway effects of stopping regular oral theophylline in patients with asthma.

Authors:  J A Bennett; J Thompson Coon; I D Pavord; P J Wilding; A E Tattersfield
Journal:  Br J Clin Pharmacol       Date:  1998-04       Impact factor: 4.335

Review 3.  Severe asthma.

Authors:  Nicholas J Kenyon; Nizar N Jarjour
Journal:  Clin Rev Allergy Immunol       Date:  2003-10       Impact factor: 8.667

Review 4.  Theophylline. Current thoughts on the risks and benefits of its use in asthma.

Authors:  S S Nasser; P J Rees
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

5.  Sequencing and comparative genomic analysis of 1227 Felis catus cDNA sequences enriched for developmental, clinical and nutritional phenotypes.

Authors:  Kristopher J Irizarry; Sukhaswami B Malladi; Xiangming Gao; Katherine Mitsouras; Lynda Melendez; Patricia A Burris; Jeffrey A Brockman; Samer W Al-Murrani
Journal:  BMC Genomics       Date:  2012-01-18       Impact factor: 3.969

6.  BSACI guidelines for the management of allergic and non-allergic rhinitis.

Authors:  G K Scadding; S R Durham; R Mirakian; N S Jones; S C Leech; S Farooque; D Ryan; S M Walker; A T Clark; T A Dixon; S R A Jolles; N Siddique; P Cullinan; P H Howarth; S M Nasser
Journal:  Clin Exp Allergy       Date:  2008-01       Impact factor: 5.018

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.